CIRM Funded Clinical Trials

Genetic Re-programming of Stem Cells to Fight Cancer


Antoni Ribas
Disease Area: 
Investigator:
CIRM Grant:
Award Value:
$19,875,776
Trial Stage: 
Phase 1
Trial Status: 
Recruiting
Targeted Enrollment:
12
ClinicalTrials.gov ID:
Details: 

There are few options for patients whose cancers have metastasized due to resistance to current therapies. This team is using gene editing technology to modify a patient’s own immune system cells and blood-forming stem cells with the aim of creating a continuous supply of immune cells that can recognize and attack hard-to-treat cancers.

Design: 

Single dose. 

Goal: 

Primary: Safety and feasibility. Secondary: Persistence of gene-marked anti-cancer immune cells

Updates: 

Enrolling.